Special Issue "Current Trends in Ginseng Research"
Deadline for manuscript submissions: closed (30 June 2017)
Dr. Anusha Chaparala
College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA
Interests: inflammatory diseases; ulcerative colitis; complementary and alternative medicine (CAM); American ginseng; panaxynol; macrophages; antioxidant; epigenetics
Prof. Dr. Woo-Sik Jeong
Department of Food and Life Sciences, Inje University, Gimhae 50834, South Korea
Interests: phytochemicals; phytochemical-drug interaction; skin health; hair growth; nutraceuticals; nutricosmetics; chemoprevention; antioxidant; detoxifying enzyme; inflammation
Ginseng (Panax genus) has been a widely used herb for centuries in Eastern Asia and has been gaining popularity in the Western world over the last decade for its therapeutic potential. Panax is derived from panacea, which means “all healing”, and this claim has been demonstrated by a number of previous and current investigations.
There are multiple known species of ginseng, and they differ in the composition of their active constituents (ginsenosides, polysaccharides, peptides, polyacetylenic alcohols, and fatty acids). There is compelling evidence to show that ginseng and its various individual components display anti-inflammatory, antioxidant, and cytotoxic properties, among others. Consequently, they have been shown to be effective in the treatment of multiple types of cancer, diabetes, and various inflammatory and cardiovascular diseases.
Although ginseng is currently placed in the category of “complementary and alternative medicine”, ongoing studies are investigating its pharmacological properties, revealing new and promising uses for ginseng and paving way for its use in mainstream medicine. This Special Issue on ginseng will focus on the past and present developments in the study of ginseng and its future prospects as a conventional therapeutic drug.
Prof. Woo-Sik Jeong
Prof. Lorne Hofseth
Dr. Anusha Chaparala
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer chemoprevention and treatment
- complementary and alternative medicine (CAM)
- drug discovery/development
- active ingredients
- cellular pathways/mechanism of action